Hilltop Holdings Inc. acquired a new stake in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $486,000. Hilltop Holdings Inc. owned approximately 0.12% of Paratek Pharmaceuticals as of its most recent SEC filing.
Several other large investors also recently modified their holdings of PRTK. Wedbush Securities Inc. purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at $144,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at $147,000. MetLife Investment Advisors LLC purchased a new stake in shares of Paratek Pharmaceuticals in the fourth quarter valued at $185,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Paratek Pharmaceuticals in the fourth quarter valued at $221,000. Finally, Hennessy Advisors Inc. purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at $331,000. Institutional investors and hedge funds own 77.49% of the company’s stock.
PRTK has been the topic of several recent analyst reports. Raymond James reiterated an “outperform” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a research report on Friday, March 2nd. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Thursday, February 22nd. Leerink Swann reiterated an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Sunday, March 4th. BidaskClub upgraded Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 14th. Finally, Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $40.00.
NASDAQ PRTK opened at $11.05 on Friday. Paratek Pharmaceuticals Inc has a twelve month low of $9.85 and a twelve month high of $29.00. The stock has a market cap of $342.82 million, a P/E ratio of -3.35 and a beta of 0.55. The company has a current ratio of 8.06, a quick ratio of 8.06 and a debt-to-equity ratio of 0.47.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.03. Paratek Pharmaceuticals had a negative return on equity of 87.29% and a negative net margin of 707.08%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.02 million. equities analysts anticipate that Paratek Pharmaceuticals Inc will post -3.68 EPS for the current year.
In other Paratek Pharmaceuticals news, COO Evan Loh sold 8,084 shares of the company’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $12.70, for a total transaction of $102,666.80. Following the completion of the sale, the chief operating officer now directly owns 214,786 shares in the company, valued at $2,727,782.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Adam Woodrow sold 5,700 shares of the company’s stock in a transaction dated Monday, April 9th. The stock was sold at an average price of $12.70, for a total value of $72,390.00. Following the sale, the vice president now owns 89,167 shares of the company’s stock, valued at $1,132,420.90. The disclosure for this sale can be found here. Insiders have sold 27,721 shares of company stock valued at $352,057 over the last 90 days. 6.20% of the stock is currently owned by insiders.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.